Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-06-12 |
2024-04 |
0 |
N/A |
N/A |
N/A |
2024-03-13 |
2024-01 |
0 |
N/A |
N/A |
N/A |
2023-12-15 |
2023-10 |
0 |
-0.11 |
N/A |
N/A |
2023-11-03 |
2023-07 |
0 |
N/A |
N/A |
N/A |
2023-06-14 |
2023-04 |
0 |
-0.31 |
N/A |
N/A |
2023-03-20 |
2023-01 |
0 |
-0.23 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2014-02-03 |
Craig-Hallum |
Upgrade |
|
Buy |
2013-07-01 |
Sidoti & Co. |
Upgrade |
|
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2022-06-13 |
BENCH DAVID A. |
Chief Financial Officer |
0.00 |
Purchase |
2024-02-22 |
CANNON KARA |
Chief Executive Officer |
496.36K |
Stock Award(Grant) |
2022-11-22 |
ERFANIAN HAMID |
Chief Executive Officer |
374.60K |
Purchase |
2021-03-15 |
HARBERT MANAGEMENT CORP |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2024-01-30 |
PULLY STEVEN J |
Director |
97.10K |
Stock Award(Grant) |
2021-01-10 |
RABBANI ELAZAR |
Chief Executive Officer |
2.26M |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Harbert Fund Advisors, Inc. |
5.18M |
9.52M |
10.41% |
2023-06-29 |
Renaissance Technologies, LLC |
2.70M |
4.98M |
5.44% |
2023-06-29 |
Tang Capital Management, LLC |
2.30M |
4.23M |
4.63% |
2023-06-29 |
Vanguard Group Inc |
1.73M |
3.18M |
3.48% |
2022-09-29 |
Viex Capital Advisors, Llc |
1.33M |
2.98M |
2.68% |
2023-06-29 |
Dimensional Fund Advisors LP |
1.27M |
2.33M |
2.55% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.04M |
1.92M |
2.09% |
2023-05-30 |
Starboard Investment Tr-Roumell Opportunistic Value Fd |
681.36K |
1.50M |
1.37% |
2023-06-29 |
Vanguard Extended Market Index Fund |
618.34K |
1.14M |
1.24% |
2023-05-30 |
Fidelity Extended Market Index Fund |
218.09K |
479.79K |
0.44% |
2023-07-30 |
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF |
214.41K |
317.33K |
0.43% |
2023-07-30 |
DFA U.S. Core Equity 2 Portfolio |
189.13K |
279.92K |
0.38% |
Dividend |
Date |
0.0661 |
1995-06-29 |
Split |
Date |
105 : 100 |
2004-10-21 |
1.05 : 1 |
2004-10-20 |
105 : 100 |
2003-06-26 |
1.05 : 1 |
2003-06-25 |
105 : 100 |
2002-01-31 |
1.05 : 1 |
2002-01-30 |